FDA granted Breakthrough Therapy designation to elironrasib, a RAS(ON) G12C-selective inhibitor, for the treatment of adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer who have received prior chemotherapy and immunotherapy but have not been previously treated with a KRAS G12C inhibitor.
At the end of July, after just a few months as director of the Center for Biologics Evaluation and Research, Vinay Prasad resigned.
